Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers

Cancer Research

Volumn 58, Issue 15, 1998, Pages 3193-3196

  Rhei, Esther ^a   Bogomolniy, Faina ^a   Federici, Mark G ^a   Maresco, Diane L ^a   Offit, Kenneth ^a   Robson, Mark E ^a   Saigo, Patricia E ^a   Boyd, Jeff ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; GENE DELETION; GENE INSERTION; GENE MUTATION; GENETIC LINKAGE; HUMAN; HUMAN TISSUE; MISSENSE MUTATION; ONCOGENE; ONCOGENE C MYC; ONCOGENE K RAS; ONCOGENE NEU; OVARY CANCER; PRIORITY JOURNAL; SOMATIC MUTATION;

ARABIDOPSIS PROTEINS; BASE SEQUENCE; BRCA2 PROTEIN; CODON; EXONS; FEMALE; GENES, BRCA1; GENES, ERBB-2; GENES, MYC; GENES, P53; GENES, RAS; GERM-LINE MUTATION; HUMANS; IMMUNOHISTOCHEMISTRY; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PLANT PROTEINS; POTASSIUM CHANNELS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032145440     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Boyd, J. Molecular genetics of hereditary ovarian cancer. Oncology (Huntingt.), 12: 399-406, 1998.
2. Tirkkonen, M., Johannsson, O., Agnarsson, B. A., Olsson, H., Ingvarsson, S., Karhu, R., Tanner, M., Isola, J., Barkardottir, R. B., Borg, A., and Kallioniemi, O-P. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res., 57: 1222-1227, 1997.
3. Marks, J. R., Davidoff, A. M., Kerns, B. J., Humphrey, P. A., Pence, J. C., Dodge, R. K., Clarke-Pearson, D., Iglehart, J. D., Bast, R. C., Jr., and Berchuck, A. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res., 51: 2979-2984, 1991.
4. Milner, B. J., Allan, L. A., Eccles, D. M., Kitchener, H. C., Leonard, R. C. F., Kelly, K. F., Parkin, D. E., and Haites, N. E. p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res., 53: 2128-2132, 1993.
5. Kupryjanczyk, J., Thor, A. D., Beauchamp, R., Merritt, V., Edgerton, S. M., Bell, D. A., and Yandell, D. W. p53 gene mutations and protein accumulation in human ovarian cancer. Proc. Natl. Acad. Sci. USA, 90: 4961-4965, 1993.
6. Kohler, M. F., Marks, J. R., Wiseman, R. W., Jacobs, I. J., Davidoff, A. M., Clarke-Pearson, D. L., Soper, J. T., Bast, R., Jr., and Berchuck, A. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J. Natl. Cancer Inst., 85: 1513-1519, 1993.
7. Casey, G., Lopez, M. E., Ramos, J. C., Plummer, S. J., Arboleda, M. J., Shaughnessy, M., Karlan, B., and Slamon, D. J. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene, 13: 1971-1981, 1996.
8. Brugarolas, J., and Jacks, T. Double indemnity: p53, BRCA and cancer. Nat. Med., 3: 721-722, 1997.
9. Sambrook, J., Fritsch, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual, 2nd ed. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 1989.
10. Boyd, J., Takahashi, H., Waggoner, S. E., Jones, L. A., Hajek, R. A., Wharton, J. T., Liu, F-S., Fujino, T., Barrett, J. C., and McLachlan, J. A. Molecular genetic analysis of clear cell adenocarcinomas of the vagina and cervix associated and unassociated with diethylstilbestrol exposure in utero. Cancer (Phila.), 77: 507-513, 1995.
11. Neubauer, A., Neubauer, B., He, M., Effert, P., Iglehart, D., Frye, R. A., and Liu, E. Analysis of gene amplification in archival tissue by differential polymerase chain reaction. Oncogene, 7: 1019-1025, 1992.
12. Benjamin, I., Saigo, P., Finstad, C., Takahashi, H., Federici, M., Rubin, S. C., and Boyd, J. Expression and mutational analysis of P53 in stage IB and IIA cervical cancers. Am. J. Obstet. Gynecol., 175: 1266-1271, 1996.
13. Kohler, M. F., Kerns, B. J., Humphrey, P. A., Marks, J. R., Bast, R., Jr, and Berchuck, A. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet. Gynecol., 81: 643-650, 1993.
14. Zhang, H., Tombline, G., and Weber, B. L. BRCA1, BRCA2, and DNA damage response: collision or collusion? Cell, 92: 433-436, 1998.
15. Ludwig, T., Chapman, D. L., Papaioannou, V. E., and Efstratiadis, A. Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev., 11: 1226-1241, 1997.
16. 5-6 early embryonic lethality by p53 or p21 null mutation. Nat. Genet., 16: 298-302, 1997.
17. Connor, F., Bertwistle, D., Mee, P. J., Ross, G. M., Swift, S., Grigorieva, E., Tybulewicz, V. L. J., and Ashworth, A. Tumorigenesis and a DNA repair detect in mice with a truncating Brca2 mutation. Nat. Genet., 17: 423-430, 1997.
18. Crook, T., Crossland, S., Crompton, M. R., Osin, P., and Gusterson, B. A. p53 mutations in BRCA1-associated familial breast cancer. Lancet, 350: 638-639, 1997.
19. Gretarsdottir, S., Thorlacius, S., Valgardsdottir, R., Gudlaugsdottir, S., Sigurdsson, S., Steinarsdottir, M., Gunnlaugur Jonasson, J., Anamthawat-Jonsson, K., and Eyfjörd, J. E. BRCA2 and p53 mutations in primary breast cancer in relation to genetic instability. Cancer Res., 58: 859-862, 1998.
20. Berchuck, A., Elbendary, A., Havrilesky, L., Rodriguez, G. C., and Bast, R. C. Pathogenesis of ovarian cancers. J. Soc. Gynecol. Invest., 1: 181-190, 1994.